NIKKEI 225
39,706.08 +532.93 (+1.36%) HANG SENG
18,113.28 +40.38 (+0.22%) CRUDE OIL
81.31 +0.48 (+0.59%) GOLD FUTURES
2,328.00 -2.80 (-0.12%) DOW
39,112.16 -299.05 (-0.76%) Bitcoin GBP
48,582.61 +307.18 (+0.64%)
REGN Jul 2024 990.000 call
| Previous close | 80.50 |
| Open | 80.50 |
| Bid | 82.60 |
| Ask | 91.00 |
| Strike | 990.00 |
| Expiry date | 2024-07-19 |
| Day's range | 80.50 - 80.50 |
| Contract range | N/A |
| Volume | |
| Open interest | 32 |
Simply Wall St.Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Could Be 45% Below Their Intrinsic Value Estimate
Key Insights The projected fair value for Regeneron Pharmaceuticals is US$1,936 based on 2 Stage Free Cash Flow to...
ZacksRegeneron (REGN) Outperforms Industry YTD: What Lies Ahead?
Regeneron (REGN) maintains momentum on the back of Dupixent profits and efforts to develop oncology portfolio despite near-term challenges.
GlobeNewswireUpdated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response or better and a 71% overall response rate, as presented in an EHA oral presentation and simultaneously published in the Journal of Clinical Oncology Also presented at EHA, a retrospective study of patient outcomes that compared investigational linvoseltamab to real-world standard-of-care treatment in clinical practice TARRYTOWN, N.Y., June 16, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.
